SCHEMBL3066836

SCHEMBL3066836

O=S(=O)(Cl)c1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.79

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.79
SMN1; SMN2 Q16637 2/20 0.79
ALDH1A1 P00352 6/20 0.74
KDM4E B2RXH2 1/20 0.74
CYP2C9 P11712 1/20 0.74
EDNRA P25101 1/20 0.74
SLC6A4 P31645 1/20 0.74
ADRA1A P35348 1/20 0.74
PRMT6 Q96LA8 1/20 0.74
TDP1 Q9NUW8 1/20 0.74
CYP1A2 P05177 1/20 0.67
PKM P14618 5/20 0.65
KMT2A Q03164 4/20 0.63
MEN1 O00255 3/20 0.63
ATM Q13315 1/20 0.62
PPIA P62937 2/20 0.61
TSHR P16473 1/20 0.56
SCN3A Q9NY46 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL184078 0.85 ALDH1A1 (0.72) LMNASMN1; SMN2ALDH1A1KDM4ECYP2C9
SCHEMBL183995 0.85 ALDH1A1 (0.72) LMNASMN1; SMN2ALDH1A1KDM4ECYP2C9
Sulfathiazole SCHEMBL30130508 0.85 ALDH1A1 (1.00) LMNASMN1; SMN2ALDH1A1KDM4ECYP2C9
SCHEMBL8388562 0.85 PPIA (0.76) LMNASMN1; SMN2ALDH1A1KDM4ECYP2C9
SCHEMBL13180843 0.85 ALDH1A1 (0.72) LMNASMN1; SMN2ALDH1A1KDM4ECYP2C9
SCHEMBL1650814 0.85 ALDH1A1 (0.72) LMNASMN1; SMN2ALDH1A1KDM4ECYP2C9
Sulfathiazole SCHEMBL94165 0.85 ALDH1A1 (1.00) LMNASMN1; SMN2ALDH1A1KDM4ECYP2C9
SCHEMBL326633 0.85 ALDH1A1 (0.71) LMNASMN1; SMN2ALDH1A1KDM4ECYP2C9
Sulfathiazole SCHEMBL468436 0.84 ALDH1A1 (0.97) LMNASMN1; SMN2ALDH1A1KDM4ECYP2C9
Sulfathiazole SCHEMBL2194108 0.84 ALDH1A1 (0.97) LMNASMN1; SMN2ALDH1A1KDM4ECYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140357685-A1 Sodium Channel Inhibitors ICAGEN INC (US) 2014-12-04 US disclosed
US-20140357685-A1 Sodium Channel Inhibitors ICAGEN INC (US) 2014-12-04 US disclosed
US-20140357685-A1 Sodium Channel Inhibitors ICAGEN INC (US) 2014-12-04 US disclosed
US-8853250-B2 Sodium channel inhibitors ICAGEN, INC. (US) 2014-10-07 US disclosed
US-8853250-B2 Sodium channel inhibitors ICAGEN, INC. (US) 2014-10-07 US disclosed
US-8853250-B2 Sodium channel inhibitors ICAGEN, INC. (US) 2014-10-07 US disclosed
EP-2175728-B1 SODIUM CHANNEL INHIBITORS ICAGEN INC (US) 2014-09-10 EP disclosed
US-8338608-B2 Inhibitors of ion channels ICAGEN INC. (US) 2012-12-25 US disclosed
US-8338608-B2 Inhibitors of ion channels ICAGEN INC. (US) 2012-12-25 US disclosed
US-8338608-B2 Inhibitors of ion channels ICAGEN INC. (US) 2012-12-25 US disclosed
EP-2175728-A1 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-21 EP disclosed
WO-2009012241-A1 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed
EP-1945029-A2 INHIBITORS OF ION CHANNELS Icagen, Inc. (US) 2008-07-23 EP disclosed
US-20070135493-A1 INHIBITORS OF ION CHANNELS ICAGEN (US) 2007-06-14 US disclosed
US-20070135493-A1 INHIBITORS OF ION CHANNELS ICAGEN (US) 2007-06-14 US disclosed
US-20070135493-A1 INHIBITORS OF ION CHANNELS ICAGEN (US) 2007-06-14 US disclosed
WO-2007056099-A2 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2007-05-18 WO disclosed
US-20050176712-A1 Integrin expression inhibitor EISAI CO., LTD. 2005-08-11 US disclosed
US-20040018192-A1 Integrin expression inhibitors EISAI CO., LTD. (JP) 2004-01-29 US disclosed
EP-1258252-A1 INTEGRIN EXPRESSION INHIBITORS Eisai Co., Ltd. (JP) 2002-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176712-A1 Integrin expression inhibitor ITGB5, ITGB1, ITGB2 LMNA 3673/4885SMN1; SMN2 2639/4885ALDH1A1 1256/4885
US-20070135493-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 LMNA 3442/4885SMN1; SMN2 445/4885ALDH1A1 3113/4885
US-20040018192-A1 Integrin expression inhibitors ITGB1, ITGB4, ITGB5 LMNA 3427/4885SMN1; SMN2 2404/4885ALDH1A1 1266/4885
US-20140357685-A1 Sodium Channel Inhibitors TRPV1, SCN1A, SCN2A LMNA 3041/4885SMN1; SMN2 326/4885ALDH1A1 2837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.